Crossmark

Can we rely on contrast-enhanced CT to identify pancreatic ductal adenocarcinoma? A population-based study in sensitivity and factors associated with false negatives

Crossref DOI link: https://doi.org/10.1007/s00330-023-09758-y

Published Online: 2023-06-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

LeBlanc, Max

Kang, Jessie

Costa, Andreu F. https://orcid.org/0000-0003-1683-8230
License Information

Text and Data Mining valid from 2023-06-02

Version of Record valid from 2023-06-02
More Information

Article History

Received: 7 December 2022

Revised: 20 March 2023

Accepted: 27 March 2023

First Online: 2 June 2023

Declarations

:

: The scientific guarantor of this publication is Dr. Andreu Costa, MD MSc FRCPC.

: Max LeBlanc, Jessie Kang, and Andreu Costa declare no relationships with any companies whose products or services may be related to the subject matter of the article.

: No complex statistical methods were necessary for this paper.

: The need for informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained.

: Yes. There are 154 subjects in this study, and these are a subset of 257 patients reported in a previous study accepted to European Radiology (Ms. No. EURA-D-20-00568). The prior study evaluated the implications in patient outcomes with respect to a missed or misinterpreted imaging examination, be it US, CT or MRI.In this study, we evaluated the sensitivity of contrast-enhanced CT to detect pancreatic cancer, and assessed factors associated with a false negative result.

:

Document is current

Any future updates will be listed below